A5004318484- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Liver Diseases and Immunity
- Renal Diseases and Glomerulopathies
- Pharmacological Effects of Natural Compounds
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Reproductive System and Pregnancy
- Cytokine Signaling Pathways and Interactions
- Pregnancy and Medication Impact
- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Skin Diseases and Diabetes
- Immune Cell Function and Interaction
- Lipid metabolism and disorders
- Adrenal Hormones and Disorders
- Vasculitis and related conditions
- Eosinophilic Disorders and Syndromes
University of Beira Interior
2015-2025
Hospitais da Universidade de Coimbra
2016-2025
University of Coimbra
2010-2024
Administração Regional de Saúde de Lisboa e Vale do Tejo
2024
Sapienza University of Rome
2022-2023
Nicosia General Hospital
2023
University of Nicosia
2023
Janssen (United States)
2023
Johnson & Johnson (United States)
2023
Zuyderland Medisch Centrum
2022
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
The new Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria aimed to improve the performance of systemic lupus erythematosus (SLE) over American College Rheumatology (ACR) 1997 criteria. However, SLICC need further external validation. Our objective was compare sensitivity for SLE between ACR and sets in a real-life, multicenter, international population.We conducted cross-sectional observational study patients with clinical diagnosis followed at...
To derive and validate a new disease activity measure for systemic lupus erythematosus (SLE), the SLE Disease Activity Score (SLE-DAS), with improved sensitivity to change as compared Index (SLEDAI), while maintaining high specificity easiness of use.We studied 520 patients from two tertiary care centres (derivation validation cohorts). At each visit, was scored using Physician Global Assessment (PGA) SLEDAI 2000 (SLEDAI-2K). construct SLE-DAS, we applied multivariate linear regression...
Objectives There is an unmet need for accurate and user-friendly definitions of systemic lupus erythematosus (SLE) disease activity remission. We aimed to derive validate the SLE Disease Activity Score (SLE-DAS) categories clinical remission state. Methods Derivation was conducted at Padova Lupus Clinic (Italy). Validation prospectively performed Cochin (France) by post hoc analysis BLISS-76 trial. At each clinic, expert classified patients in three categories: remission, mild or...
Objective. SLE has a relapsing–remitting course with disease activity flares over time. This study aims to identify clinical predictors of flares.
Central nervous system (CNS) vasculitis in systemic erythematosus lupus (SLE) is a rare and challenging diagnosis. We report four cases of CNS that occurred 5 to 16 years after the diagnosis SLE. Magnetic resonance imaging (MRI) detected different features suggestive vasculitis: enhancement thickening vascular wall, stenosis, ischemic brain lesions intracerebral haemorrhage unlikely correspond other mimic aetiologies. Three patients received combination therapy with glucocorticoids (GC)...
Standard induction therapy for lupus nephritis (LN) with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) is often ineffective. Evidence on rescue regimens scarce. We analyzed efficacy and tolerability of multitarget immunosuppression MMF cyclosporine A (CsA) as treatment LN (class III/IV/V) refractory to CYC and/or MMF. included all six patients IV = 3, class V 2, III 1) from our 400-patient tertiary Lupus Clinic observed between 2012 2015. Four had previously received pulse CYC. All...
The objective of this paper is to evaluate the performance Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) in detecting clinically meaningful changes SLE disease activity.A longitudinal cohort study was conducted 334 patients during a 36-month follow-up. At each outpatient visit, activity scored using Physician Global Assessment (PGA) and SLEDAI-2K. Correlations between PGA SLEDAI-2K were assessed. A change defined as ΔPGA ≥ 0.3 points from baseline. Performance worsening or...
Dear Editor, anti-Ku antibodies (abs) have been associated with several CTD, mainly SLE and inflammatory myositis. However, abs are rare, just a few studies small number of patients focused on their clinical correlates [1, 2]. Spielmann et al., in study 42 positive patients, identified autoantibody biomarkers two CTD subsets, rarely overlapping, implications for management: anti-Ku-positive elevated creatine kinase (CK) levels having high risk interstitial lung diseases (ILDs), anti-dsDNA...
The purpose of our study was to evaluate the frequency leukocyte count abnormalities in a large cohort SLE patients and its association with infection. To make this evaluation, we studied consecutive diagnosis prospectively followed them Coimbra Lupus Cohort. Data about white blood cell infection during one‐year follow‐up were obtained. presence leukopenia, lymphopenia, neutropenia registered for period. Infections classified as severe or mild. We found that 124 who included (91.1% female,...
Background: Although the survival rate has considerably improved, many patients with systemic lupus erythematosus (SLE) develop irreversible organ damage. Objectives: The objectives of this paper are to characterize cumulative damage in SLE and identify variables associated its presence severity. Methods: A cross-sectional analysis from Portuguese Lupus register Reuma.pt/SLE whom assessment using SLICC/ACR-Disability Index (SDI) was available performed. Predictor factors for damage, defined...
Abstract Objectives To identify predictors of complete renal response (CRR) and flares in SLE patients with active proliferative LN. Methods This was a retrospective cohort study over 36 months including biopsy-proven LN (class III/IV), from two European tertiary centres. CRR flare were defined as proteinuria <0.5 g/day normal function >1 after attainment, respectively. Demographic, clinical analytic parameters evaluated early outcome, using survival analysis. Candidate...
To derive and validate a definition of low disease activity (LDA) for SLE based on the Disease Activity Score (SLE-DAS), in real-life multicentre cohort patients.Derivation was conducted using data from monocentric (Portugal), validation performed (Italy, France Spain). The Lupus Low State (LLDAS) used as comparator. We applied receiver operating characteristics curve analysis against LLDAS to determine cut-off SLE-DAS LDA bootstrap methodology. In second step, we tested that included: (i)...
The creation of a physician-administered questionnaire to screen patients with Systemic Lupus Erythematosus (SLE) for the presence symptoms suggestive neuropsychiatric involvement (NPSLE).The development followed three phases. First, list manifestations was prepared based on ACR case definitions NPSLE. A first constructed including 119 items. To reduce their number, Delphi analysis carried out and second 62 questions developed. This administered 139 SLE (58 NPSLE: 29 active, inactive; 81...